Glomerular ACE2 expression was lower in patients with DN or IgAN compared to healthy controls [26–28], whereas glomerular ACE2 expression in patients with other forms of CKD—specifically, focal segmental glomerulosclerosis (FSGS), chronic allograft nephropathy, minimal change disease (MCD), MGN, and HN—was similar to that of control subjects [26, 28, 29]. Here, ACE2 is linked to liver dysplastic nodule.